Orbis Medicines used a series of LinkedIn updates and its “In the Loop” newsletter to align itself with the fast-emerging field of oral biologics and macrocycle therapeutics. Management repeatedly highlighted Johnson & Johnson’s recent U.S. FDA approval of Icotyde, an oral macrocycle IL-23 receptor antagonist for psoriasis, as a key validation point for the modality.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Across the communications, Orbis underscored the remaining hurdles for oral biologics, including improving bioavailability, achieving scalable manufacturing, and competing with entrenched injectable therapies. The company framed these challenges as areas where its nGen platform, described as a programmable, data-driven engine for discovering orally bioavailable macrocycles, aims to provide an advantage.
The company also announced plans to participate in the upcoming Bio€quity Europe conference in Prague, organized by BioCentury Inc. and EBD Group. CEO Morten Graugaard is expected to use the event to engage with biotech innovators, investors, and potential partners, signaling an active business development and partnering agenda around Orbis’s platform.
Orbis’s latest newsletter edition expanded on the commercial potential of oral biologics, including an oral GLP-1 case study and implications of the approaching patent cliff for major therapies. The content emphasized how next-generation oral modalities could capture value as incumbent biologics lose exclusivity, positioning Orbis conceptually within this future opportunity set.
While the updates did not disclose specific pipeline assets, financial data, or concrete deals, they collectively portray Orbis as an early participant in a technology trend that is gaining regulatory and commercial validation. If the nGen platform can materially improve discovery efficiency and success rates, the company could be better placed to secure collaborations, licensing agreements, or future financing as the oral biologics market evolves.